PURPOSE: Histone deacetylase inhibitors (HDACis) are a promising class of anticancer agents for the treatment of brain tumors. HDACis can increase the expression of brain-derived neurotrophic factor (BDNF) in brain cells. We have previously shown that BDNF reduces the viability of medulloblastoma cells. The aim of the present study was to examine the effect of the HDACi sodium butyrate (NaB) combined with human recombinant BDNF (hrBDNF), on the viability of human medulloblastoma cell lines. METHODS: DAOY and ONS76 medulloblastoma cells were treated with NaB, hrBDNF, or NaB combined with hrBDNF. Cell viability was measured with the MTT assay. RESULTS: NaB combined with hrBDNF significantly reduced the viability of DAOY medulloblastoma cells. In ONS76 cells, NaB alone reduced viability, but the effect was not potentiated by hrBDNF. CONCLUSION: These findings provide early evidence for a rationale supporting further evaluation of HDACis and BDNF as a new combinatorial approach to inhibit the growth of medulloblastoma.
PURPOSE: Histone deacetylase inhibitors (HDACis) are a promising class of anticancer agents for the treatment of brain tumors. HDACis can increase the expression of brain-derived neurotrophic factor (BDNF) in brain cells. We have previously shown that BDNF reduces the viability of medulloblastoma cells. The aim of the present study was to examine the effect of the HDACi sodium butyrate (NaB) combined with human recombinant BDNF (hrBDNF), on the viability of humanmedulloblastoma cell lines. METHODS: DAOY and ONS76 medulloblastoma cells were treated with NaB, hrBDNF, or NaB combined with hrBDNF. Cell viability was measured with the MTT assay. RESULTS:NaB combined with hrBDNF significantly reduced the viability of DAOY medulloblastoma cells. In ONS76 cells, NaB alone reduced viability, but the effect was not potentiated by hrBDNF. CONCLUSION: These findings provide early evidence for a rationale supporting further evaluation of HDACis and BDNF as a new combinatorial approach to inhibit the growth of medulloblastoma.
Authors: Xiao-Nan Li; Qin Shu; Jack Men-Feng Su; Laszlo Perlaky; Susan M Blaney; Ching C Lau Journal: Mol Cancer Ther Date: 2005-12 Impact factor: 6.261
Authors: K Tamura; K Shimizu; M Yamada; Y Okamoto; Y Matsui; K C Park; E Mabuchi; S Moriuchi; H Mogami Journal: Cancer Res Date: 1989-10-01 Impact factor: 12.701
Authors: X M He; S X Skapek; C J Wikstrand; H S Friedman; J Q Trojanowski; J T Kemshead; H B Coakham; S H Bigner; D D Bigner Journal: J Neuropathol Exp Neurol Date: 1989-01 Impact factor: 3.685
Authors: Xuefei Wu; Po See Chen; Shannon Dallas; Belinda Wilson; Michelle L Block; Chao-Chuan Wang; Harriet Kinyamu; Nick Lu; Xi Gao; Yan Leng; De-Maw Chuang; Wanqin Zhang; Ru Band Lu; Jau-Shyong Hong Journal: Int J Neuropsychopharmacol Date: 2008-07-09 Impact factor: 5.176
Authors: Jürgen Sonnemann; K Saravana Kumar; Sandra Heesch; Cornelia Müller; Christoph Hartwig; Manfred Maass; Peter Bader; James F Beck Journal: Int J Oncol Date: 2006-03 Impact factor: 5.650
Authors: Martina Blank; Fernanda S Petry; Martina Lichtenfels; Fernanda E Valiati; Arethuza S Dornelles; Rafael Roesler Journal: J Neural Transm (Vienna) Date: 2015-10-01 Impact factor: 3.575
Authors: Kelly V Pinheiro; Amanda Thomaz; Bárbara Kunzler Souza; Victoria Anne Metcalfe; Natália Hogetop Freire; André Tesainer Brunetto; Caroline Brunetto de Farias; Mariane Jaeger; Victorio Bambini; Christopher G S Smith; Lisa Shaw; Rafael Roesler Journal: Mol Biol Rep Date: 2020-08-29 Impact factor: 2.316
Authors: Tiago Elias Heinen; Rafael Pereira Dos Santos; Amanda da Rocha; Michel Pinheiro Dos Santos; Patrícia Luciana da Costa Lopez; Marco Aurélio Silva Filho; Bárbara Kunzler Souza; Luís Fernando da Rosa Rivero; Ricardo Gehrke Becker; Lauro José Gregianin; Algemir Lunardi Brunetto; André Tesainer Brunetto; Caroline Brunetto de Farias; Rafael Roesler Journal: Oncotarget Date: 2016-06-07